Bone Biologics
BBLG
3 hedge funds and large institutions have $160K invested in Bone Biologics in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$83.3K |
| 2 |
Jane Street
New York
|
+$32.6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$25.4K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $93K | +$83.3K | +23 | New |
|
|
2
Jane Street
New York
| $37K | +$32.6K | +9 | New |
|
|
3
Citadel Advisors
Miami,
Florida
| $30K | +$25.4K | +7 | New |
|
BBLG Hedge Fund Activity: Q1 2022 in Review
3 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q1 2022, worth a combined $160K.
Buyers outnumbered sellers: 3 funds opened new BBLG positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $83.3K.
- 3 institutional investors held Bone Biologics (BBLG) as of Q1 2022, up from 0 in Q4 2021.
- Funds reported $160K of Bone Biologics stock for Q1 2022.
- 3 funds opened new Bone Biologics positions in Q1 2022 and 0 closed out, a net change of +3 holders.
- The largest Bone Biologics buyer in Q1 2022 was Vanguard Group, an estimated $83.3K added.
Based on aggregated 13F filings for Q1 2022.